The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia-Reference-Cited by-同舟云学术

The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia

Published:2017-03-24 Issue:10 Volume:31 Page:2211-2218
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Eisfeld A-K,Mrózek K,Kohlschmidt J,Nicolet D,Orwick S,Walker C J,Kroll K W,Blachly J S,Carroll A J,Kolitz J E,Powell B L,Wang E S,Stone R M,de la Chapelle A,Byrd J C,Bloomfield C D

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/leu201786.pdf

Reference50 articles.

1. Döhner H, Weisdorf DJ, Bloomfield CD . Acute myeloid leukemia. N Engl J Med 2015; 373: 1136–1152.

2. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo myeloid leukemia. N Engl J Med 2013; 368: 2059–2074.

3. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 2016; 374: 2209–2221.

4. Metzeler KH, Herold T, Rothenberg-Thurley M, Amler S, Sauerland MC, Görlich D et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. Blood 2016; 128: 686–698.

5. Stone R, Mandrekar S, Sanford BL, Geyer S, Bloomfield CD, Dohner K et al. The multi-kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)/cytarabine (C) induction (ind), high-dose C consolidation (consol), and as maintenance (maint) therapy in newly diagnosed acute myeloid leukemia (AML) patients (pts) age 18-60 with FLT3 mutations (muts): an international prospective randomized (rand) p-controlled double-blind trial (CALGB 10603/RATIFY [Alliance]). Blood 2015; 126: (abstract 6).

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications – a HARMONY study;Leukemia;2024-07-04

2. Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study;Blood Cancer Journal;2024-05-31

3. Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study.;2024-04-09

4. Case report: One case of acute myeloid leukemia M3 with atypical morphology;Frontiers in Oncology;2024-03-19

5. Appraisal of current technologies for the study of genetic alterations in hematologic malignancies with a focus on chromosome analysis and structural variants;Medizinische Genetik;2024-03-04